Emerging and established therapies for chemotherapy-induced ototoxicity

Guthrie, O’neil W.; Spankovich, Christopher

doi:10.1007/s11764-022-01317-6

Cited by 8 publications

(1 citation statement)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[27,28] In chemotherapy, the adjunct therapy is found to be more bene cial and the use of vitamins and minerals as an add-on drug may provide a good tolerance effect. [29,30] A necessary nutrient with antioxidant qualities is vitamin C, sometimes referred to as ascorbic acid. Although its primary functions are immune system support and skin health promotion, there has been considerable investigation into its potential as a co-drug or complementary therapy in speci c medical situations.…”

Section: Introductionmentioning

confidence: 99%

Vitamin C induced DNA cleavage using curcumin loaded Fe3O4-silane magnetic nanoparticles

Prabakaran,

Mareeswaran,

Shanmugavelan

2024

Preprint

View full text Add to dashboard Cite

The loading and unloading of a drug into a nanoparticle is the first stage in the delivery of a nanodrug. This work investigates the loading of curcumin via soft hydrolysis of silane using iron oxide-silane core-shell nanoparticles. Additionally, the study examines the sustained release of curcumin from the core-shell nanoparticles over a period of 70 hours at a physiological pH. The release ability is studied using absorption spectral technique. The interaction of DNA is studied using emission spectral technique. Drug delivery applications should involve interactions between the released drug and the biomolecules of the biological systems. Therefore, this system is used to study the interaction between curcumin and DNA and vitamin C-induced cleavage.

show abstract

Section: Introductionmentioning

confidence: 99%

Vitamin C induced DNA cleavage using curcumin loaded Fe3O4-silane magnetic nanoparticles

Prabakaran,

Mareeswaran,

Shanmugavelan

2024

Preprint

View full text Add to dashboard Cite

show abstract

The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy

Duinkerken,

Chiodo,

Hueniken

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

BackgroundConcomitant high‐dose cisplatin with radiotherapy is commonly used for treating head and neck squamous cell carcinoma (HNSCC). Cisplatin, often used with radiotherapy, is known for causing irreversible sensorineural hearing loss, with individual variability suggesting a genetic component. This study aims to enhance the predictive ability of the clinical prediction model for cisplatin‐induced hearing loss (CIHL) in HNSCC patients, as outlined in Theunissen et al., by incorporating significant genetic variants.MethodsConducted at the Netherlands Cancer Institute, this retrospective study included 74 patients treated between 1997 and 2011. Thirty‐one SNPs that were previously associated with CIHL or other cisplatin‐induced toxicities were identified and incorporated into the model. The primary outcome measured was the change in decibels at posttreatment 1‐2‐4 kHz hearing levels per additional minor allele of these SNPs, evaluated using linear mixed‐effects regression models. The model's predictive accuracy was determined by the area under the curve (AUC) using 10‐fold cross‐validation.ResultsThe rs2289669 SNP in the SLC47A1/MATE1 gene was linked to a significant 2.67 dB increase in hearing loss per allele (95% CI 0.49–4.86, p = 0.017). Incorporating rs2289669 improved the model's AUC from 0.78 to 0.83, a borderline significant improvement (p = 0.073).ConclusionsThis study underscores the importance of the rs2289669 SNP in CIHL and demonstrates the potential of combining genetic and clinical data for enhanced predictive models in personalized treatment strategies.

show abstract

Treatment-related hearing loss in weekly versus triweekly cisplatin chemoradiation for head and neck cancer

Burger,

Duinkerken,

van Sluis

et al. 2024

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

Purpose Cisplatin-induced hearing loss is a common side effect in patients treated with cisplatin-based chemoradiation (CRT) for head and neck squamous cell carcinoma. The extent of hearing loss after concurrent CRT was compared between triweekly (3 × 100 mg/m2) and weekly (7 × 40 mg/m2) cisplatin CRT. Method This retrospective cohort study was conducted in the Antoni van Leeuwenhoek Hospital and included 129 patients with cisplatin-based CRT for head and neck cancer (72 treated in the triweekly and 57 in the weekly regimen). Baseline and follow-up pure tone audiometry was conducted to assess hearing loss. Clinically relevant hearing loss was defined as a decline upon treatment of ≥ 10 decibel at a pure tone average 1-2-4 kHz and/or 8-10-12.5 kHz. Results The incidence of clinically relevant cisplatin CRT induced hearing loss was 42% in the triweekly versus 19% in the weekly group (p < 0.01). The mean threshold shift at a pure tone average (PTA) 1-2-4 kHz was 9.0 decibel in the triweekly compared to 4.3 decibel in the weekly CRT group (p < 0.01). At PTA 8-10-12.5 kHz, the incidence of clinically relevant hearing loss was 75% in the triweekly compared to 74% in the weekly CRT group (p = 0.87). The mean threshold shift at PTA 8-10-12.5 kHz was 20.2 decibel versus 15.6 decibel, respectively (p = 0.07). Conclusion Cisplatin-dose reduction to a weekly cisplatin CRT regimen for head and neck cancer may reduce the incidence of clinically relevant hearing loss at frequencies vital for speech perception.

show abstract

Emerging and established therapies for chemotherapy-induced ototoxicity

Cited by 8 publications

References 83 publications

Vitamin C induced DNA cleavage using curcumin loaded Fe3O4-silane magnetic nanoparticles

Vitamin C induced DNA cleavage using curcumin loaded Fe3O4-silane magnetic nanoparticles

The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy

Treatment-related hearing loss in weekly versus triweekly cisplatin chemoradiation for head and neck cancer

Contact Info

Product

Resources

About